NO20025035L - Oksadiazolderivater som har anticancer-effekter - Google Patents

Oksadiazolderivater som har anticancer-effekter

Info

Publication number
NO20025035L
NO20025035L NO20025035A NO20025035A NO20025035L NO 20025035 L NO20025035 L NO 20025035L NO 20025035 A NO20025035 A NO 20025035A NO 20025035 A NO20025035 A NO 20025035A NO 20025035 L NO20025035 L NO 20025035L
Authority
NO
Norway
Prior art keywords
oxadiazole derivatives
anticancer effects
anticancer
effects
oxadiazole
Prior art date
Application number
NO20025035A
Other languages
English (en)
Other versions
NO324868B1 (no
NO20025035D0 (no
Inventor
Takayuki Yoshioka
Ryuji Maekawa
Fumihiko Watanabe
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NO20025035D0 publication Critical patent/NO20025035D0/no
Publication of NO20025035L publication Critical patent/NO20025035L/no
Publication of NO324868B1 publication Critical patent/NO324868B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20025035A 2000-04-21 2002-10-18 Oksadiazolderivater som har anticancer-effekt samt farmasoytisk preparat NO324868B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000120234 2000-04-21
PCT/JP2001/003214 WO2001083463A1 (fr) 2000-04-21 2001-04-16 Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaires

Publications (3)

Publication Number Publication Date
NO20025035D0 NO20025035D0 (no) 2002-10-18
NO20025035L true NO20025035L (no) 2002-12-19
NO324868B1 NO324868B1 (no) 2007-12-17

Family

ID=18631080

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025035A NO324868B1 (no) 2000-04-21 2002-10-18 Oksadiazolderivater som har anticancer-effekt samt farmasoytisk preparat

Country Status (16)

Country Link
US (2) US6720343B2 (no)
EP (1) EP1277744A4 (no)
JP (1) JP3974781B2 (no)
KR (1) KR100542780B1 (no)
CN (1) CN1199956C (no)
AU (2) AU2001246916B2 (no)
BR (1) BR0110211A (no)
CA (1) CA2406685C (no)
HU (1) HUP0300619A3 (no)
MX (1) MXPA02010325A (no)
NO (1) NO324868B1 (no)
PL (1) PL203161B1 (no)
RU (1) RU2275371C2 (no)
TW (1) TWI294877B (no)
WO (1) WO2001083463A1 (no)
ZA (1) ZA200208307B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
EP1650199A4 (en) * 2003-07-30 2008-11-19 Shionogi & Co SULPHONAMIDE DERIVATIVE WITH ISOXAZOL RING
US7659294B2 (en) * 2004-10-22 2010-02-09 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
KR20090007792A (ko) * 2006-05-09 2009-01-20 화이자 프로덕츠 인크. 시클로알킬아미노산 유도체 및 이들의 제약 조성물
KR100783585B1 (ko) 2006-08-22 2007-12-07 한국생명공학연구원 스탯의 활성을 저해하는 옥사다이아졸 우레아 화합물을 유효성분으로 함유하는 암의 예방 또는 치료제
JP5718053B2 (ja) 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド 治療用イソオキサゾール化合物
CA2706834A1 (en) * 2007-12-10 2009-06-18 Actelion Pharmaceuticals Ltd Thiophene derivatives as agonists of s1p1/edg1
AR077969A1 (es) 2009-08-31 2011-10-05 Abbott Healthcare Products Bv Derivados de (tio)morfolina comomoduladores de s1p
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
CN103450167A (zh) * 2012-05-28 2013-12-18 南京大学 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
EP4051683A1 (en) 2019-10-31 2022-09-07 Escape Bio, Inc. Solid forms of an s1p-receptor modulator
CN113264899B (zh) * 2021-04-09 2022-06-14 台州学院 一种1，3，5-噁二嗪类化合物及其制备和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69836877D1 (de) 1997-07-22 2007-02-22 Shionogi & Co Verwendung von Matrix- Metalloproteinase Inhibitoren zur Behandlung oder Vorbeugung von Glomerulopathie
WO2000015213A1 (fr) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Agent de prevention ou de traitement de l'insuffisance cardiaque congestive

Also Published As

Publication number Publication date
JP3974781B2 (ja) 2007-09-12
US20030203940A1 (en) 2003-10-30
CN1199956C (zh) 2005-05-04
MXPA02010325A (es) 2003-04-25
CA2406685C (en) 2006-10-31
TWI294877B (no) 2008-03-21
AU4691601A (en) 2001-11-12
KR100542780B1 (ko) 2006-01-11
NO324868B1 (no) 2007-12-17
HUP0300619A3 (en) 2006-02-28
CA2406685A1 (en) 2002-10-17
KR20030019357A (ko) 2003-03-06
PL203161B1 (pl) 2009-08-31
BR0110211A (pt) 2003-06-03
NO20025035D0 (no) 2002-10-18
AU2001246916B2 (en) 2004-10-07
CN1436179A (zh) 2003-08-13
PL359415A1 (en) 2004-08-23
RU2275371C2 (ru) 2006-04-27
EP1277744A1 (en) 2003-01-22
ZA200208307B (en) 2003-10-15
US20040122066A1 (en) 2004-06-24
EP1277744A4 (en) 2007-07-11
WO2001083463A1 (fr) 2001-11-08
HUP0300619A2 (hu) 2003-07-28
US6720343B2 (en) 2004-04-13

Similar Documents

Publication Publication Date Title
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
NO20025035L (no) Oksadiazolderivater som har anticancer-effekter
NO20030055D0 (no) Colchinolderivater som angiogenese inhibitorer
NO20032531D0 (no) Tetralon-derivater som antitumormidler
DK1414440T3 (da) N-phenylpyrrolguanidinderivater som melanocortinreceptorligander
NL1017075A1 (nl) Preparaat.
NO20032473D0 (no) Sulfonamidoetersubstituerte imidazokinoliner
NO20030153L (no) Blandinger som inneholder terapeutisk aktive komponenter som har foröket löselighet
NL1018546A1 (nl) Stabilisatormengsels.
DK1284974T3 (da) Triazolyltropanderivater som CCR5-modulatorer
NO20032613D0 (no) Farmasöytisk sammensetning som har en forbedret vannopplöselighet
NO20015078L (no) Sulfonamidderivater som har oksadiazolringer
DK1322654T3 (da) Platinkomplekser som antitumormidler
NL1018186A1 (nl) Stabilisatormengsels.
DK1165547T3 (da) Substituerede benzoylpyrazoler som herbicider
NL1018187A1 (nl) Stabilisatormengsels.
NO20013441D0 (no) Sammensetninger som har forbedret stabilitet
NO20031387L (no) O-substituerte 6-metyl-tramadolderivater
NL1018188A1 (nl) Stabilisatormengsels.
DK1322608T3 (da) Delta1-Pyrroliner som pesticider
NO20030474D0 (no) Demens-legemiddel som inneholder 2-aryl-8- oksodihydropurinderivater som denaktive bestanddel
NO20023211D0 (no) Underholdningsmaskiner
ES1045332Y (es) Bandeja-expositor para estanteria.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees